Abstract:Background Mycoplasma pneumoniae is one of the main causes of community-acquired pneumonia. Due to the imperfect immune system of children, this also causes Mycoplasma pneumoniae pneumonia (MPP) to be more common in children. Globally, the incidence of MPP in children is gradually increasing. This study was the first to systematically review the clinical efficacy and safety of Shuanghuanglian (SHL) oral preparations combined with azithromycin in the treatment of MPP in children. Methods This study fully retrieved 3 Chinese databases and 5 English databases to search the randomized controlled trials (RCTs) of SHL oral preparations combined with azithromycin in the treatment of children with MPP. The search time is from the inception to September 2020. Data extraction and risk bias evaluation were performed independently by two researchers. We conducted a Meta-analysis of all the outcome indicators. Besides, Meta-regression, subgroup analysis, and heterogeneity analysis were used for the primary outcomes to find the possible potential confounding factors. Results Finally, we included 27 RCTs involving 2884 patients. SHL oral preparations combined with azithromycin were better than azithromycin alone in response rate (RR = 1.14, 95% CI[1.11, 1.18]; low certainty evidence), disappearance time of fever(MD = -1.72, 95% CI[-2.47, -0.97]; low certainty evidence), disappearance time of cough (MD = -2.95, 95% CI[-3.55, -2.34]; low certainty evidence), and disappearance time of pulmonary rales (MD = -2.13, 95% CI[-2.88, -1.38]; low certainty evidence). The Meta-regression results showed that the course of disease, age, and method of administration may be the source of heterogeneity. Subgroup analysis and sensitivity analysis have found that the results were stable. For other related clinical symptoms, T lymphocytes, and Serum inflammatory factors, SHL oral preparations combined with azithromycin was better than azithromycin alone, and the difference was statistically significant. For adverse events with low certainty evidence, safety needs further verification. Conclusion Based on the results of meta-analysis with low certainty evidence, we believed that SHL oral preparations combined with azithromycin likely be effectively improved clinical symptoms compared with azithromycin alone. Low certainty evidence showed that SHL may safety with no serious adverse events. Due to these limitations, the safety needs further verification. More high-quality, multicenter, and large-sample RCTs should be tested and verified in the future.

Clinical Efficacy of Azithromycin in the Treatment of Pediatric Mycoplasma pneumoniae Pneumonia and Its Impact on Platelet Count and D-Dimer Levels

The Effect of Azithromycin in Treating Mycoplasma Pneumonia in Children

Clinical Efficacy of Azithromycin in Treatment of Children’s Mycoplasma Pneumonia

The Timing Of Azithromycin Treatment Is Not Associated With The Clinical Prognosis Of Childhood Mycoplasma Pneumoniae Pneumonia In High Macrolide-Resistant Prevalence Settings

Analysis of the Efficacy of Erythromycin Cyclic 11,12-Carbonate Combined with Azithromycin in the Treatment of Severe Mycoplasma Pneumoniae Pneumonia in Children and its Effect on Cytokines

Efficacy of Azithromycin plus Glucocorticoid Adjuvant Therapy on Serum Inflammatory Factor Levels and Incidence of Adverse Reactions in Children with Mycoplasma Pneumonia

Effect of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia

EFFECT OF COMBINATION OF METHYLPREDNISOLONE AND AZITHROMYCIN ON PEDIATRIC MYCOPLASMA PNEUMONIA AND ITS EFFECTS ON PROCALCITONIN, HS-CRP, CARDIAC TROPONIN AND IL-2

Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children

Effects and safety of Azithromycin sequential therapy in the treatment of mycoplasma pneumonia in children

Efficacy and safety of Azithromycin and Erythromycin for respiratory mycoplasma infection in children: a meta-analysis

Xiao’er Xiaoji Zhike Oral Liquid Combined with Azithromycin for Mycoplasma Pneumoniae Pneumonia in Children: A Systematic Review and Meta-Analysis

Study on the Therapeutic Effect of Azithromycin Combined with Glucocorticoid on Pulmonary Function and Inflammatory Response in Children with Pneumonia

Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children

Erythromycin Cydocarbonate improvement of clinical symptoms of mycoplasma pneumonia and analysis of immunoglobulin level changes and mechanism

Clinical Effect Comparison Between Treatment Transformation of Azithromycin and Erythromycin for Children with Mycoplasma Pneumonia

Efficacy and safety of azithromycin combined with glucocorticoid on refractory<i>Mycoplasma pneumoniae</i>pneumonia in children A PRISMA-compliant systematic review and meta-analysis

Xiyanping Plus Azithromycin Chemotherapy in Pediatric Patients with Mycoplasma Pneumoniae Pneumonia: A Systematic Review and Meta-Analysis of Efficacy and Safety

The efficacy of azithromycin combined with seven types of Chinese medicine injections in the treatment of Mycoplasma pneumoniae pneumonia in children: a systematic review and Bayesian network meta-analysis

Azithromycin Effectiveness in Children with Mutated Mycoplasma Pneumoniae Pneumonia

Shuanghuanglian oral preparations combined with azithromycin for treatment of Mycoplasma pneumoniae pneumonia in Asian children: A systematic review and meta-analysis of randomized controlled trials